Prakt. lékáren. 2013; 9(3): 110-112

Retigabine (Trobalt®): a novel antiepileptic agent to treat pharmacoresistant focal epilepsy

Robert Kuba
1 Centrum pro epilepsie Brno, 1. neurologická klinika LF MU FN u svaté Anny, Brno
2 Středoevropský technologický institut (CEITEC), Masarykova univerzita, Brno

Retigabine is the most recent antiepileptic agent to have been introduced in the Czech market. It has a unique mechanism of action

that involves inhibition of neuronal potassium channels. Based on the results of controlled clinical trials, its administration is indicated

for the adjunctive treatment of adult patients with focal epilepsy with focal or secondarily generalized tonic-clonic seizures. The drug

is administered by mouth three times a day in daily doses of 600 to 1 200 mg after previous titration. The most common adverse effects

include dizziness, sleepiness, headache, and fatigue.

Keywords: retigabine, pharmacoresistant epilepsy, novel antiepileptic agents

Published: July 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kuba R. Retigabine (Trobalt®): a novel antiepileptic agent to treat pharmacoresistant focal epilepsy. Pharmacy for Practice. 2013;9(3):110-112.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Barrese V, Miceli F, Soldovieri MV, et al. Neuronal K+ channel openers in the management of epilepsy: role and potential of Retigabine. Clin Pharmacol 2010; 2: 225-236. Go to original source...
    2. Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010; 75: 1817-1824. Go to original source... Go to PubMed...
    3. French JA, Abou-Khalil BW, Leroy RF, et al. Randomized double-blind placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011; 76: 1555-1563. Go to original source... Go to PubMed...
    4. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009; 61: 197-216. Go to original source... Go to PubMed...
    5. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007; 4: 18-81. Go to original source... Go to PubMed...
    6. Porter RJ, Burdette DE, Gil-Nagel A, et al. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. Epilepsy Res 2012; 101: 103-112. Go to original source... Go to PubMed...
    7. Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007; 68: 1197-1204. Go to original source... Go to PubMed...
    8. Tikoo D, Gupta M. Retigabine (Ezogabine) for management of partial onset seizures: A mini review. Int J Pharmacol ad Clin Sci 2012; 1: 85-90.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.